Tci Wealth Advisors, Inc. Affimed N.V. Transaction History

Tci Wealth Advisors, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$3.69 - $5.65 $2,269 - $3,474	-615 Closed	0 $0
Q4 2021 Jan 24, 2022	BUY	$5.37 - $7.07 $3,302 - $4,348	615 New	615 $3,000
Q3 2021 Oct 29, 2021	SELL	$5.54 - $7.51 $1,595 - $2,162	-288 Closed	0 $0
Q2 2021 Aug 02, 2021	BUY	$7.78 - $11.4 $2,240 - $3,283	288 New	288 $2,000
Q1 2018 Apr 30, 2018	SELL	$1.25 - $2.65 $625 - $1,325	-500 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	500	500 $1,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.